908 Devices develops handheld and desktop mass spectrometry instruments and bioprocess monitoring systems for life sciences research, pharmaceutical manufacturing, and forensic applications. The company's product portfolio includes the MX908, a battery-powered handheld mass spectrometer designed for rapid field analysis of solids, liquids, vapors, and aerosols; the Rebel desktop analyzer for real-time bioprocess monitoring; and the Maverick optical analyzer for tracking glucose, lactate, and biomass levels in mammalian cell cultures. The company also offers the Maven and Trace C2 systems for fermentation monitoring and the ZipChip high-resolution separation platform to optimize mass spectrometry sample analysis.
908 Devices operates across multiple markets including biopharma, bioprocessing, pharmaceutical quality control, and forensics. The company maintains a presence in North America, Europe, the Middle East, Africa, and Asia Pacific, with headquarters in Burlington, Massachusetts. As of the latest available data, the company employs approximately 246 people. 908 Devices was incorporated in Delaware in 2012 and trades on the Nasdaq exchange.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-2.12 | $-2.12 | -87.6% | |
| 2023 | $-1.13 | $-1.13 | -5.6% | |
| 2022 | $-1.07 | $-1.07 | -35.4% | |
| 2021 | $-0.79 | $-0.79 | — |